It's time to break the ice on pharmacy benefit managers' "drink the Kool-Aid" rhetoric! Join Pharmacists United for Truth & Transparency as we host guests from across the healthcare industry to discuss pharmacy news, healthcare issues, & (of course) PBMs... over cocktails.
…
continue reading
Join Employers Health's Chief Strategy Officer, Mike Stull, for our podcast on all things HR and employee benefits related. We'll cover your most frequently asked human resource questions, benefits best practices, our unique employer-led group purchasing program for pharmacy benefits management and more. We want this to be your podcast, with content that is relevant to you and your organization. Therefore, we invite you to submit questions or topics of interest that you would like covered in ...
…
continue reading
Welcome to PBM Unplugged, the podcast that takes you behind the scenes of the pharmacy benefit management industry. Join us as we delve into strategies, insider tips, and expose corruption within the world of prescription drug benefits. We aim to empower employers, providers, and payers with the knowledge they need to navigate this complex landscape effectively. Get ready to uncover the truth and gain valuable insights on maximizing prescription drug benefits. This is PBM Unplugged. Together ...
…
continue reading
Join the movement! The Basic Christian is a discussion of sharing the gospel to the ends of the earth as well as learning to love God and mankind.
…
continue reading
Subject matter experts on controlling the administrative costs of healthcare while improving health outcomes.
…
continue reading
Healthcare innovations that make a difference. On the show, Cristy Gupton, President of Custom Benefits Solutions, meets with other experts in the industry and talks over solutions to current obstacles. Today's problems with healthcare and how we change it for the better.
…
continue reading
A podcast that covers all things related to cancer. Providing inspiration, education, benefit and so much more to anyone linked to cancer in any way, shape or form.
…
continue reading
The Off Script podcast offers in-depth interviews and discussions with industry experts about hot-button topics in pharma, and goes behind the scenes of Pharma Manufacturing’s print and online coverage, which follows the industry’s biggest issues surrounding scale-up, technology innovations, regulations and more
…
continue reading
American Healthcare Entrepreneurs and Execs you might want to know. Talking. Relentless Health Value is a weekly interview podcast hosted by Stacey Richter, a healthcare entrepreneur celebrating fifteen years in the business side of healthcare. This show is for leaders in pharma, devices, payers, providers, patient advocacy and healthcare business. It's for health industry innovators, entrepreneurs or wantrepreneurs or intrapreneurs. Relentless Healthcare Value is the show for you if you wan ...
…
continue reading
Independent pharmacies are the last line of defense between patients and a pharmacy system that is quickly becoming a monopoly. The Independent Pharmacy Alliance Podcast will explore why Americans pay the highest drug prices in the world, highlight the life-saving services independent pharmacies provide, and how Pharmacy Benefit Managers utilize anti-competitive business practices to increase drug prices. In each episode, we‘ll talk to a pharmacist or front-line worker fighting for patients ...
…
continue reading
Healthcare is Hard: A Podcast for Insiders views healthcare transformation through the lens of prominent leaders across the industry. Through intimate one-on-one discussions with executives, policy advisors, and other “insiders,” each episode dives deep into the pressing challenges that come with changing how we care for people. Hear the unique perspectives of these industry leaders to get a better understanding of what is happening today, the challenges across the healthcare ecosystem, and ...
…
continue reading
Measures of central tendency
…
continue reading
NFP introduces the Insights from the Experts podcast series. Each episode will showcase timely perspective from members of the NFP community, delivering information, analysis and solutions that address our clients’ most significant challenges. You can find archived episodes of Innovation Conversations at https://soundcloud.com/user-939810789.
…
continue reading
JC Scott, President & CEO of the Pharmaceutical Care Management Association, discusses the latest trends, public policy developments, and political challenges impacting drug pricing and healthcare. You'll hear the nation's top thought leaders, policy experts, and political analysts on topics like how employers, unions, and others use Pharmacy Benefit Managers (PBMs) to drive value for their members in the face of growing healthcare costs. You'll also learn about advancements in gene therapy, ...
…
continue reading
![Artwork](/static/images/128pixel.png)
1
PBMs, Patients & Protests (Oh My!) LIVE episode
1:05:14
1:05:14
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:05:14
Grab and drink & join this month's very special cocktail crew as they discuss the many reasons why this September's Friday the 13th protest at OptumRx is so important, and how raising your voice about the issues is crucial for advocating across the healthcare spectrum. Special Guests: Angry Dad Bil Schmidtknecht (@angrydadwi), AIDS Healthcare Found…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Chris Lewis - Blood Cancer survivor and founder of the Simpal charity
41:19
41:19
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
41:19
Chris is an incredible guy. He tells an amazing story about his journey following a blood cancer diagnosis. Chris faced the news at one point that he may only have 6 months to live but beat the odds and is now all clear and in full health. Chris is yet another cancer survivor that has gone on to do some incredible work, helping others. Chris set up…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
EP448 (Part 2): 340B: Why Employers Should Probably Care About What’s Happening Here, With Shawn Gremminger
25:39
25:39
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
25:39
First of all, we got two really nice reviews lately. One is from Doug Geinzer. Hi, Doug! Doug wrote, “[Relentless Health Value is] a must listen. There are just a few podcasts that I listen to religiously [and] Relentless Health Value is one of those.” He goes on to say we have a knack for “finding the brightest of the bright and asking the right q…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
EP448 (Part 1): 340B: Where It Started, Where It Is Now, and Who Is Really Benefiting From This Massive Program, With Shawn Gremminger
37:57
37:57
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
37:57
So, after some pondering, I decided to release this conversation with Shawn Gremminger about 340B in two parts. So, listen to one, listen to both, pick your poison. Shawn Gremminger came up with three really important takeaways relative to 340B, which is a feat unto itself, considering how sprawling this conversation can be. So, if you came here fo…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
FDA approves Illumina cancer biomarker test, BioMarin reveals more layoffs, FDA hits API maker Global Calcium with 483 [The good, the bad, the ugly]
3:30
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Illumina cancer biomarker test The bad — BioMarin reveals more layoffs The ugly — FDA hits API maker Global Calcium with 483Von Pharma Manufacturing
…
continue reading
![Artwork](/static/images/128pixel.png)
1
S03E14: Need Care for a Complicated Diagnosis? It Shouldn't Be This Hard.
48:43
48:43
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
48:43
Von Cristy Gupton
…
continue reading
![Artwork](/static/images/128pixel.png)
1
The Euphemism That Has Become Value-Based Care, With Elizabeth Mitchell—Summer Shorts 9
17:14
17:14
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
17:14
In this Summer Short Episode of Relentlessly Seeking Value, host Stacey Richter discusses the hidden costs and inefficiencies of value-based care with Elizabeth Mitchell, President and CEO of the Purchaser Business Group on Health (PBGH). To read the full article and show notes which include mentioned links, visit the episode page. If you enjoy thi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
What’s the Difference Between Innovation and Performance Improvement?
38:00
38:00
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
38:00
OSF HealthCare stands as a model health system for those who want to do innovation right. One of the defining characteristics of the Peoria, Illinois-based system is how it aligns innovation with operations for everyone – all 24,000 employees across 159 locations, including 16 hospitals. Becky Buchen is responsible for driving innovation at OSF Hea…
…
continue reading
The concept of healthspan has recently gained new attention in the pharma industry and rightfully so, given the surprisingly large chasm in the U.S. between average years lived (77.5) and average years lived in good health (63.9). Facing a growing demographic of unhealthy seniors, a handful of innovative biotechs are reframing the longevity discuss…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 45 - Ask Mike Anything - Your Pharmacy Benefit Questions Answered
37:46
37:46
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
37:46
In this episode of HR Benecast, Mike Stull and Eric Dublikar cover your pharmacy and employee benefits questions including: What's new in federal and state pharmacy benefit legislation. How Employers Health is working to help clients manage changes to their PBM plans. What the switch to biosimilars for Humira and Stelara means for plan sponsors. Wh…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Emergent donates 50k doses of mpox vaccine to Africa, FDA rejects Regeneron blood cancer bispecific antibody, China indicts Astellas exec for espionage [The good, the bad, the ugly]
3:41
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Emergent donates 50,000 doses of mpox vaccine to Africa The bad — FDA rejects Regeneron blood cancer bispecific antibody The ugly — China indicts Astellas exec for espionage…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Encore! EP413: The Intersection of Healthcare Waste, Value-Based Care, and the Potential Rising Power of PCPs, With Will Shrank, MD
34:41
34:41
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
34:41
My conversation today is with Will Shrank, MD. Dr. Shrank led the evaluation group at CMMI (Center for Medicare and Medicaid Innovation). He has spent time in the private sector, first at CVS Health and UPMC (University of Pittsburgh Medical Center) as chief medical officer of the health plan in Pittsburgh, and then as the chief medical officer for…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
LIVE with Special Guest Mike Koelzer
1:02:19
1:02:19
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:02:19
Listen in as Lord Dr Jeremy and the PBM OTR cocktail crew host special guests Mike Koelzer, host of The Business of Pharmacy podcast, and Thu Nguyen, co-host of the podcast Hey Rx Friends We Got This Opening music by JuliusH Production by Shannon Wightman-GirardVon Pharmacists United for Truth & Transparency
…
continue reading
![Artwork](/static/images/128pixel.png)
1
FDA approves Ascendis drug, Lykos PTSD treatment rejected, Novartis bid blocked [The good, the bad, the ugly]
3:21
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Ascendis hypoparathyroidism drug The bad — FDA rejects Lykos MDMA PTSD drug The ugly — Judge blocks Novartis bid to stop generic blockbuster heart drug…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
George Light - HPV Throat cancer survivor
42:33
42:33
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
42:33
George gave an incredible interview. He was so articulate of his journey and showed amazing resilience, inspitarion, vulnerability and real emotion. George was a real natural and I always say that the best interviews are the ones where i speak less and the interviewee speaks more. This epitomises that. George gave such detail about his story and is…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Encore! EP402: What Physicians Trying to Clinically Integrate Care in the Real World Need to Know, With Amy Scanlan, MD
32:50
32:50
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
32:50
This encore episode is with Amy Scanlan, MD. It was, in fact, one of our most popular episodes of the past year. It is still just as relevant today in a slightly different way. It’s interesting how things which were said maybe a year ago have shades of meaning which become evident as time goes on. So, I liked this show a lot in the second listen wi…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Amneal's Parkinson's pill approved, Novo Nordisk withdraws Wegovy approval expansion bid, FDA delays BeiGene Tevimbra decision [The good, the bad, the ugly]
2:59
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Amneal gets FDA nod for Parkinson’s pill The bad — Novo Nordisk withdraws bid for Wegovy label expansion in heart failure The ugly — FDA delays decision on BeiGene Tevimbra as a first-line therapy…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Applying Pressure, PBM Perjury, and an Empty Bottle of Irish Whiskey
1:00:46
1:00:46
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:00:46
Join this month's PBM Reform cocktail crew as they discuss PBM exec lies during the recent Congressional hearing, the FTC Open Commission meeting, and why applying pressure at both the state and federal levels is so critical to getting real, enforceable reform across the finish line! Special Guest, Massachusetts pharmacy owner, Joe Chammas Opening …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
EP447: Why an “EHR Strategy” Isn’t Enough, With Ashleigh Gunter
28:44
28:44
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
28:44
In Episode 447, Stacey Richter interviews Ashleigh Gunter, president of Translucent Healthcare Consulting, to discuss the indispensable role of change management in healthcare transformation. They emphasize that creating an effective change strategy involves great leadership, a clear case for change, influential change champions, over-communication…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Axe RX - A Discount Card That Can Help Make You Money
16:18
16:18
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
16:18
Many discount card programs are scams. Independent pharmacists can get burned when patients use these cards because they lose money. Al Branca works with Axe Rx and says that this program is different. This week Anthony talks with Al and he explains what makes Axe Rx different, how it can help you avoid audits, and why it's worth at least trying.…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
FDA approves Adaptimmune therapy, halts vTv diabetes program; Sanofi sues Sarepta over Duchenne patents [The good, the bad, the ugly]
3:58
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Adaptimmune engineered cell therapy The bad — FDA puts clinical hold on vTv Therapeutics diabetes program The ugly — Sanofi sues Sarepta over manufacturing patents for Duchenne gene ther…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
EP446: Hey, Let’s Not Talk About EHRs, With Spencer Dorn, MD, MPH, MHA
34:37
34:37
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
34:37
In Episode 446, "Hey, Let's Not Talk About EHRs," host Stacey Richter engages Dr. Spencer Dorn, vice chair and professor of medicine at the University of North Carolina, in a comprehensive discussion about the implications of healthcare technology, specifically electronic health records (EHRs). Visit the Episode Page to read the show notes with men…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
FDA approves Sun Pharma hair loss drug, FDA issues warning letter to Brassica, EMA rejects Eisai-Biogen Alzheimer's drug [The good, the bad, the ugly]
3:46
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA approves Sun Pharma hair loss drug The bad — FDA issues harsh warning letter to Indian CDMO Brassica The ugly — EMA issues negative opinion on Eisai-Biogen Alzheimer's drug…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
EP445: Can a Primary-Care-Only Practice Survive in 2024? With Tom X. Lee, MD
47:53
47:53
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
47:53
I wanted to talk with Dr. Lee because so many RHV (Relentless Health Value) listeners are trying to figure out how to sustain primary care as a stand-alone entity when the most obvious and most common way to make enough money in primary care is to drive and maximize the dollars from downstream volume of high-priced service lines, which, if you thin…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Special FTC Episode LIVE with Matt Stoller
1:05:05
1:05:05
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:05:05
Join our host Lord Dr Jeremy as he discusses PBM antitrust issues, and the newly released FTC 6b study interim report with experts Matt Stoller and Greg Reybold. Opening music by JuliusHVon Pharmacists United for Truth & Transparency
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Genentech's oral weight loss drug shows promise; FDA denies accelerated approval for Agenus' cancer drug; Orexo's opioid overdose drug rejected again [The good, the bad, the ugly]
3:35
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Genentech's oral weight loss drug shows promise The bad — FDA denies accelerated approval for Agenus' cancer drug The ugly — Orexo's opioid overdose drug rejected again…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Encore! EP397: The Minefield That Is a PBM Contract and Also Some Advice for EBCs Who Are Taking Money Under the Table, With Paul Holmes
34:15
34:15
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
34:15
In this encore episode of 'Relentlessly Seeking Value,' host Stacey Richter revisits a critically important conversation with ERISA attorney Paul Holmes about the complexities and hidden pitfalls in Pharmacy Benefit Manager (PBM) contracts. Aimed at CFOs and employer plan sponsors, Holmes highlights how poorly reviewed PBM contracts can lead to com…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Help or Harm? How CHAI is Mitigating the Risk of AI in Healthcare
54:30
54:30
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
54:30
With great power comes great responsibility and in healthcare, those words may have never held more meaning than they do with the advent of artificial intelligence. AI most certainly has the power to transform healthcare, and those in the industry working to develop and use it have an immense responsibility to shape principles that ensure these tec…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Pfizer advances obesity pill, FDA rejects Novo insulin, FTC releases PBM report [The good, the bad, the ugly]
3:28
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Pfizer advances once-daily obesity pill The bad — FDA rejects Novo Nordisk once-weekly insulin The ugly — FTC releases long-awaited report on PBMsVon Pharma Manufacturing
…
continue reading
![Artwork](/static/images/128pixel.png)
1
EP444: Two State Healthcare Laws Often Don’t Go as Planned: CON and COPA, With Ann Kempski
35:19
35:19
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
35:19
In Episode 444 of Relentless Health Value, Stacey Richter speaks with healthcare consultant Ann Kempski about two state healthcare laws with unintended consequences: the Certificate of Need (CON) and the Certificate of Public Advantage (COPA) laws. They delve into the original intentions behind these laws, the ways in which they have often failed, …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Lilly Alzheimer’s drug gets full approval, Rocket gene therapy rejected, Eisai, BMS end ADC partnership [The good, the bad, the ugly]
3:44
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — FDA grants Eli Lilly Alzheimer’s drug full approval The bad — FDA rejects Rocket gene therapy The ugly — Eisai, BMS end ADC partnershipVon Pharma Manufacturing
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Communication, Aggregate Data, and a Dry IPA July
1:06:41
1:06:41
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
1:06:41
Join Lord Dr Jeremy and this month's cocktail crew as they discuss the importance of communication in advocacy, the newly released 3Axis report, and how PUTT is offering solutions to the PBM problem. Special Guests: pharmacy owners & PUTT Executive Board members Brandi Chane and Lauren Young Opening music by JuliusH Production & Editing by Shannon …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
EP443: Let Us Never Pay the First Bill in Honor of Marshall Allen
36:17
36:17
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
36:17
To read the full show notes with links mentioned, be sure to visit our episode page and consider signing up for our free weekly newsletter. Episode 443 of Relentless Health Value pays tribute to the late Marshall Allen, an investigative journalist dedicated to exposing injustices within the American healthcare system. Hosted by Stacey Richter, the …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
[Solutions Spotlight] Streamlining oral dose packaging design
31:57
31:57
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
31:57
By integrating a Quality by Design (QbD) approach, developers can design robust packaging from the outset, drastically reducing development time and costs. Understanding how moisture affects a product is key, allowing developers to use industry-accepted and validated models to predict and address potential stability issues early in the design phase…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Episode 44 - Pharmacy Benefit Rebate Credit
25:06
25:06
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
25:06
This episode features Employers Health Chief Operating Officer, Zach Hostetler. He joins our Chief Sales Officer, Mike Stull to discuss pharmacy benefit rebate credits and why they exist. They'll cover how rebate credits are calculated, how long we can expect rebate credits to be around, how Employers Health is working to validate the value of the …
…
continue reading
![Artwork](/static/images/128pixel.png)
1
Verona wins COPD nod, FDA rejects Merck-Daiichi ADC, Glenmark recalls potassium chloride capsules [The good, the bad, the ugly]
3:42
Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week: The good — Verona wins FDA nod for COPD The bad — FDA issues CRL to Merck-Daiichi lung cancer ADC The ugly — Glenmark recalls 114 batches of potassium chloride capsules…
…
continue reading
![Artwork](/static/images/128pixel.png)
1
EP442: A Short Rumination on Saving Money, Except Not Saving Money. Oncology Side Effect Management as a Case Study, With Andreas Mang
18:51
18:51
Später Spielen
Später Spielen
Listen
Gefällt mir
Geliked
18:51
In Episode 442 of 'Relentless Health Value,' host Stacey Richter shares an intriguing outtake from a previous episode featuring Andreas Mang, senior managing director at Blackstone, discussing the critical issue of cost management in oncology side effect treatment. The conversation delves into the inefficiencies and patient harms caused by inadequa…
…
continue reading